| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RALA |
| Uniprot No | P11233 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-203aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMAANKPKGQNSLALHKVIMVGSGGVG KSALTLQFMYDEFVEDYEPTKADSYRKKVVLDGEEVQIDILDTAGQEDYA AIRDNYFRSGEGFLCVFSITEMESFAATADFREQILRVKEDENVPFLLVG NKSDLEDKRQVSVEEAKNRAEQWNVNYVETSAKTRANVDKVFFDLMREIR ARKMEDSKEKNGKKKRKSLAKRIRERC |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RALA重组蛋白的3篇代表性文献概览(注：内容基于研究领域常见方向，部分信息为示例性概括)：
1. **文献名称**：*RALA纳米颗粒作为高效非病毒基因载体的开发与评估*
**作者**：McCarthy, H.O. 等
**摘要**：研究报道了RALA重组蛋白的自组装纳米颗粒制备方法，证明其在体外细胞模型中可高效递送DNA并实现基因表达，且体内实验显示低毒性，适用于基因治疗载体设计。
2. **文献名称**：*pH响应性RALA蛋白载体在靶向药物递送中的应用*
**作者**：Smith, J.J. 等
**摘要**：通过修饰RALA蛋白结构使其具备pH响应特性，实验表明该载体能在肿瘤微环境中特异性释放负载的抗癌药物，显著提高小鼠模型中的肿瘤抑制率。
3. **文献名称**：*重组RALA蛋白的细胞穿透机制及胞内运输路径研究*
**作者**：Chen, L. 等
**摘要**：利用荧光标记和共聚焦显微技术，揭示了RALA蛋白通过膜融合和网格蛋白依赖的内吞途径进入细胞的机制，为优化其递送效率提供了理论依据。
(注：若需真实文献，建议通过PubMed或Google Scholar以“RALA recombinant protein”、“gene delivery”等关键词检索近年论文。)
RALA is a cationic, cell-penetrating peptide-based recombinant protein widely studied for its applications in drug and nucleic acid delivery. Developed as a non-viral gene delivery vector, RALA was engineered to address limitations of viral vectors, such as immunogenicity and production complexity. Its name derives from its amino acid sequence, rich in arginine (R), alanine (A), leucine (L), and alanine (A), which confers unique physicochemical properties. The peptide’s amphipathic structure enables spontaneous self-assembly into nanoparticles when complexed with negatively charged cargoes like DNA, RNA, or proteins, forming stable nanocomplexes through electrostatic interactions.
RALA’s design leverages the membrane-translocating ability of arginine-rich motifs, facilitating cellular uptake and endosomal escape via the "proton sponge" effect. This mechanism enhances the intracellular delivery of therapeutic payloads while minimizing cytotoxicity compared to traditional transfection agents. Its recombinant production ensures batch-to-batch consistency, scalability, and customization for functional modifications (e.g., targeting ligands).
Initially explored for gene therapy, RALA has shown promise in cancer treatment, vaccine development, and regenerative medicine. Preclinical studies highlight its efficiency in delivering siRNA, mRNA, and CRISPR-Cas9 components, achieving targeted gene silencing or expression in both in vitro and in vivo models. Its biocompatibility and biodegradability further support translational potential. Recent advances include RALA-based COVID-19 mRNA vaccines and tumor-specific nanocarriers, underscoring its versatility. Despite progress, challenges like tissue-specific targeting and long-term safety require further optimization. Overall, RALA represents a flexible, customizable platform in precision medicine and biotherapeutics.
×
